HC Wainwright reiterated their buy rating on shares of Selecta Biosciences (NASDAQ:SELB) in a report released on Tuesday morning, TipRanks reports. HC Wainwright currently has a $6.00 target price on the stock.
Several other analysts have also recently issued reports on the stock. Needham & Company LLC boosted their price objective on shares of Selecta Biosciences from $6.00 to $7.00 and gave the company a buy rating in a research note on Monday, November 1st. Zacks Investment Research cut shares of Selecta Biosciences from a hold rating to a sell rating in a research note on Saturday, November 13th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Buy and an average target price of $6.54.
NASDAQ:SELB opened at $2.77 on Tuesday. The firm has a 50-day moving average price of $3.21 and a two-hundred day moving average price of $3.79. Selecta Biosciences has a twelve month low of $2.61 and a twelve month high of $5.70. The company has a market capitalization of $323.12 million, a P/E ratio of -5.33 and a beta of 1.04.
In other news, Director Timothy A. Springer acquired 3,748,000 shares of the company’s stock in a transaction dated Thursday, December 9th. The shares were bought at an average price of $3.06 per share, with a total value of $11,468,880.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Carsten Brunn sold 13,597 shares of the business’s stock in a transaction on Wednesday, January 5th. The stock was sold at an average price of $3.09, for a total value of $42,014.73. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 3,985,782 shares of company stock valued at $12,179,692 and have sold 42,848 shares valued at $129,655. Insiders own 24.00% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc raised its position in shares of Selecta Biosciences by 39.0% during the second quarter. Legal & General Group Plc now owns 9,512 shares of the company’s stock worth $40,000 after purchasing an additional 2,668 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Selecta Biosciences during the second quarter worth $45,000. Natixis acquired a new stake in shares of Selecta Biosciences during the third quarter worth $47,000. Squarepoint Ops LLC acquired a new stake in shares of Selecta Biosciences during the second quarter worth $49,000. Finally, WNY Asset Management LLC purchased a new position in shares of Selecta Biosciences during the third quarter valued at $49,000. 72.41% of the stock is currently owned by institutional investors.
About Selecta Biosciences
Selecta Biosciences, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.